查看購物車
  • Simplified Chinese
  • English
  • Japanese
  • Korean
封面
市場調查報告書
商品編碼
1604756

自體免疫疾病治療藥物市場：按適應症、藥物類別、分佈分類 - 全球預測 2025-2030

Autoimmune Disease Drugs Market by Indication (Diabetes Mellitus Type 1, Multiple Sclerosis, Rare Diseases), Drug Class (Anti-Inflammatory, Antihyperglycemic, Immunosuppressants), Distribution - Global Forecast 2025-2030
出版日期: | 出版商: 360iResearch | 英文 187 Pages | 商品交期: 最快1-2個工作天內

價格

※ 本網頁內容可能與最新版本有所差異。詳細情況請與我們聯繫。

2023年自體免疫疾病治療市值為1,087.1億美元，預估2024年將達1,167.9億美元，複合年成長率為7.52%，至2030年將達1,806.7億美元。

自體免疫疾病治療市場包括旨在治療免疫系統錯誤攻擊健康細胞的各種自體免疫疾病的藥物的開發、生產和分銷。這些藥物對於對抗類風濕性關節炎、多發性硬化症和狼瘡等慢性疾病以及改善患者的生活品質至關重要。由於遺傳傾向、環境影響和生活方式改變等因素，全球自體免疫疾病的盛行率不斷增加，推動了對自體免疫療法的需求。這些藥物的範圍涵蓋醫院、診所和居家醫療，最終使用者包括醫療機構和有持續治療需求的個人。市場成長主要歸功於生物技術的進步，導致生技藥品和生物相似藥等創新藥物的開發。不斷成長的醫療保健支出、患者意識和診斷能力也對市場擴張做出了重大貢獻。潛在的機會在於新興市場和透過藥物基因組學實現的個人化醫療，這使得能夠根據患者的基因譜進行客製化治療。然而，市場面臨著藥品成本上漲、嚴格的法規環境以及自體免疫疾病的複雜性等挑戰，這些挑戰使治療通訊協定變得複雜。此外，專利到期和生物相似藥的出現可能會加劇競爭。創新可能發生在替代藥物傳輸系統、研究微生物組在自體免疫反應中的作用以及開發副作用較少的藥物等領域。製藥公司和學術機構之間的合作研究可能會激發新的發現。了解市場的複雜性至關重要，因為它的特點是技術快速進步和不斷變化的監管環境。尋求創新和主導的主要企業將能夠透過投資研發、專注於策略聯盟和優先考慮以患者為中心的方法，在這個充滿活力的領域成功發展。

主要市場統計
基準年[2023] 1087.1億美元
預計年份 [2024] 1167.9億美元
預測年份 [2030] 1806.7億美元
複合年成長率（%） 7.52%

市場動態：揭示快速發展的自體免疫疾病藥物市場的關鍵市場洞察

供需的動態交互作用正在改變自體免疫疾病治療市場。透過了解這些不斷變化的市場動態，公司可以準備好做出明智的投資決策、完善策略決策並抓住新的商機。全面了解這些趨勢可以幫助企業降低政治、地理、技術、社會和經濟領域的風險，同時也能幫助消費行為及其對製造業的影響。

  • 市場促進因素
    • 類風濕性關節炎、格雷夫茲病和橋本甲狀腺病等自體免疫疾病的盛行率增加
    • 人們對自體免疫疾病的認知不斷增強
    • 完善政府支持、資助和報銷政策
  • 市場限制因素
    • 與自體免疫疾病治療藥物相關的副作用
  • 市場機會
    • 後期管道藥物的進展和可用性
    • 自體免疫疾病治療的持續研究與技術創新
  • 市場挑戰
    • 自體免疫疾病藥物高成本

波特五力：駕馭自體免疫疾病藥物市場的策略工具

波特的五力框架是了解市場競爭格局的重要工具。波特的五力框架為評估公司的競爭地位和探索策略機會提供了清晰的方法。該框架可幫助公司評估市場動態並確定新業務的盈利。這些見解使公司能夠利用自己的優勢，解決弱點並避免潛在的挑戰，從而確保更強大的市場地位。

PESTLE分析：了解自體免疫疾病藥物市場的外部影響

外部宏觀環境因素在塑造自體免疫疾病治療市場的表現動態方面發揮著至關重要的作用。對政治、經濟、社會、技術、法律和環境因素的分析提供了應對這些影響所需的資訊。透過調查 PESTLE 因素，公司可以更了解潛在的風險和機會。這種分析可以幫助公司預測法規、消費者偏好和經濟趨勢的變化，並幫助他們做出積極主動的決策。

市場佔有率分析 了解自體免疫疾病治療藥物市場的競爭狀況

對自體免疫疾病治療藥物市場的詳細市場佔有率分析可以對供應商的績效進行全面評估。公司可以透過比較收益、客戶群和成長率等關鍵指標來揭示其競爭地位。該分析揭示了市場集中、分散和整合的趨勢，為供應商提供了製定策略決策所需的洞察力，以應對日益激烈的競爭。

FPNV 定位矩陣自體免疫疾病治療市場供應商的績效評估

FPNV定位矩陣是評估自體免疫疾病治療市場供應商的重要工具。此矩陣允許業務組織根據商務策略和產品滿意度評估供應商，從而做出與其目標相符的明智決策。這四個象限使您能夠清晰、準確地分類供應商，以確定最能滿足您的策略目標的合作夥伴和解決方案。

策略分析與建議，規劃自體免疫疾病治療藥物市場的成功之路

對於旨在加強其在全球市場的影響力的公司來說，對自體免疫疾病治療藥物市場的策略分析至關重要。透過考慮關鍵資源、能力和績效指標，公司可以識別成長機會並努力改進。這種方法使您能夠克服競爭環境中的挑戰，利用新的商機並取得長期成功。

本報告對市場進行了全面分析，涵蓋關鍵重點領域：

1. 市場滲透率：詳細檢視當前市場環境、主要企業的廣泛資料、評估其在市場中的影響力和整體影響力。

2. 市場開拓：辨識新興市場的成長機會，評估現有領域的擴張潛力，並提供未來成長的策略藍圖。

3. 市場多元化：分析近期產品發布、開拓地區、關鍵產業進展、塑造市場的策略投資。

4. 競爭評估與情報：徹底分析競爭格局，檢驗市場佔有率、業務策略、產品系列、認證、監理核准、專利趨勢、主要企業的技術進步等。

5. 產品開發與創新：重點在於有望推動未來市場成長的最尖端科技、研發活動和產品創新。

我們也回答重要問題，以幫助相關人員做出明智的決策：

1.目前的市場規模和未來的成長預測是多少？

2. 哪些產品、區隔市場和地區提供最佳投資機會？

3.塑造市場的主要技術趨勢和監管影響是什麼？

4.主要廠商的市場佔有率和競爭地位如何？

5. 推動供應商市場進入和退出策略的收益來源和策略機會是什麼？

目錄

第1章 前言

第2章調查方法

第3章執行摘要

第4章市場概況

第5章市場洞察

  • 市場動態
    • 促進因素
      • 自體免疫疾病類風濕性關節炎、格雷夫茲病和橋本氏症的發生率增加
      • 人們對自體免疫疾病的認知不斷增強
      • 完善政府援助、資助和報銷政策
    • 抑制因素
      • 與自體免疫疾病藥物相關的副作用
    • 機會
      • 後期管道藥物的進展和可用性
      • 自體免疫疾病治療的持續研究與創新
    • 任務
      • 自體免疫疾病藥物高成本
  • 市場區隔分析
  • 波特五力分析
  • PESTEL分析
    • 政治的
    • 經濟
    • 社群
    • 技術的
    • 合法地
    • 環境

第6章自體免疫疾病治療藥物市場（按適應症）

  • 1型糖尿病
  • 多發性硬化症
  • 罕見疾病
  • 風濕性疾病

第7章依藥物類別分類的自體免疫疾病治療藥物市場

  • 發炎（藥
  • 降血糖藥
  • 免疫抑制劑
  • 干擾素
  • 非類固醇消炎劑

第8章自體免疫疾病治療藥物市場經銷商

  • 醫院藥房
  • 網路商店
  • 零售藥房

第9章北美和南美自體免疫疾病治療市場

  • 阿根廷
  • 巴西
  • 加拿大
  • 墨西哥
  • 美國

第10章亞太地區自體免疫疾病治療市場

  • 澳洲
  • 中國
  • 印度
  • 印尼
  • 日本
  • 馬來西亞
  • 菲律賓
  • 新加坡
  • 韓國
  • 台灣
  • 泰國
  • 越南

第11章 歐洲、中東和非洲自體免疫疾病治療藥物市場

  • 丹麥
  • 埃及
  • 芬蘭
  • 法國
  • 德國
  • 以色列
  • 義大利
  • 荷蘭
  • 奈及利亞
  • 挪威
  • 波蘭
  • 卡達
  • 俄羅斯
  • 沙烏地阿拉伯
  • 南非
  • 西班牙
  • 瑞典
  • 瑞士
  • 土耳其
  • 阿拉伯聯合大公國
  • 英國

第12章競爭格局

  • 2023 年市場佔有率分析
  • FPNV 定位矩陣，2023
  • 競爭情境分析
  • 戰略分析和建議

公司名單

  • Abbott Laboratories
  • AESKU.GROUP GmbH & Co. KG
  • AstraZeneca PLC
  • Beckman Coulter, Inc.
  • Bio-Rad Laboratories, Inc.
  • BioAgilytix Labs, LLC
  • Biogenuix Medsystems Private Limited
  • bioMerieux SA
  • Exagen, Inc.
  • F. Hoffmann-La Roche AG
  • Novartis AG
  • Pfizer, Inc.
  • Sanofi SA
  • Siemens Healthineers AG
  • Thermo Fisher Scientific Inc.
  • Trinity Biotech PLC
  • Werfen SA
Product Code: MRR-436901065FE5

The Autoimmune Disease Drugs Market was valued at USD 108.71 billion in 2023, expected to reach USD 116.79 billion in 2024, and is projected to grow at a CAGR of 7.52%, to USD 180.67 billion by 2030.

The autoimmune disease drugs market encompasses the development, production, and distribution of pharmaceuticals aimed at treating a variety of autoimmune conditions, where the immune system mistakenly attacks healthy cells. These drugs are vital as they address chronic illnesses such as rheumatoid arthritis, multiple sclerosis, and lupus, improving patient quality of life. The necessity for autoimmune drugs stems from increasing incidence rates of autoimmune disorders globally, heightened by factors such as genetic predisposition, environmental influences, and lifestyle changes. The application of these drugs spans hospitals, clinics, and home care settings, with end-users including healthcare facilities and individuals requiring ongoing treatment. Market growth is largely driven by advancements in biotechnology, leading to the development of innovative drugs such as biologics and biosimilars. Increasing healthcare spending, patient awareness, and diagnostic capabilities also contribute significantly to expanding the market. Potential opportunities lie in emerging markets and the personalization of medicine through pharmacogenomics, which allows for tailored treatments based on patient genetic profiles. However, the market faces challenges, including high drug costs, stringent regulatory environments, and the complexity of autoimmune diseases which can complicate treatment protocols. Moreover, patent expirations and the emergence of biosimilars can heighten competition. Innovation is likely to thrive in areas like alternative drug delivery systems, research on the microbiome's role in autoimmune responses, and developing drugs with fewer side effects. Collaborations between pharmaceutical companies and academic institutions could fuel new discoveries. Understanding the market's intricate nature is crucial, as it is characterized by rapid technological advancements and evolving regulatory landscapes. Companies aspiring to innovate and lead should invest in R&D, focus on strategic alliances, and prioritize patient-centric approaches to successfully navigate and capture growth in this dynamic field.

KEY MARKET STATISTICS
Base Year [2023] USD 108.71 billion
Estimated Year [2024] USD 116.79 billion
Forecast Year [2030] USD 180.67 billion
CAGR (%) 7.52%

Market Dynamics: Unveiling Key Market Insights in the Rapidly Evolving Autoimmune Disease Drugs Market

The Autoimmune Disease Drugs Market is undergoing transformative changes driven by a dynamic interplay of supply and demand factors. Understanding these evolving market dynamics prepares business organizations to make informed investment decisions, refine strategic decisions, and seize new opportunities. By gaining a comprehensive view of these trends, business organizations can mitigate various risks across political, geographic, technical, social, and economic domains while also gaining a clearer understanding of consumer behavior and its impact on manufacturing costs and purchasing trends.

  • Market Drivers
    • Increasing incidence of autoimmune diseases rheumatoid arthritis, graves and hashimoto's thyroid disease
    • Growing awareness of autoimmune diseases
    • Improved government assistance, funding, and reimbursement policies
  • Market Restraints
    • Associated side effects of autoimmune disease drugs
  • Market Opportunities
    • Advancements and availability of late-stage pipeline drugs
    • Ongoing research and innovations in autoimmune disease drugs
  • Market Challenges
    • High cost of autoimmune disease medications

Porter's Five Forces: A Strategic Tool for Navigating the Autoimmune Disease Drugs Market

Porter's five forces framework is a critical tool for understanding the competitive landscape of the Autoimmune Disease Drugs Market. It offers business organizations with a clear methodology for evaluating their competitive positioning and exploring strategic opportunities. This framework helps businesses assess the power dynamics within the market and determine the profitability of new ventures. With these insights, business organizations can leverage their strengths, address weaknesses, and avoid potential challenges, ensuring a more resilient market positioning.

PESTLE Analysis: Navigating External Influences in the Autoimmune Disease Drugs Market

External macro-environmental factors play a pivotal role in shaping the performance dynamics of the Autoimmune Disease Drugs Market. Political, Economic, Social, Technological, Legal, and Environmental factors analysis provides the necessary information to navigate these influences. By examining PESTLE factors, businesses can better understand potential risks and opportunities. This analysis enables business organizations to anticipate changes in regulations, consumer preferences, and economic trends, ensuring they are prepared to make proactive, forward-thinking decisions.

Market Share Analysis: Understanding the Competitive Landscape in the Autoimmune Disease Drugs Market

A detailed market share analysis in the Autoimmune Disease Drugs Market provides a comprehensive assessment of vendors' performance. Companies can identify their competitive positioning by comparing key metrics, including revenue, customer base, and growth rates. This analysis highlights market concentration, fragmentation, and trends in consolidation, offering vendors the insights required to make strategic decisions that enhance their position in an increasingly competitive landscape.

FPNV Positioning Matrix: Evaluating Vendors' Performance in the Autoimmune Disease Drugs Market

The Forefront, Pathfinder, Niche, Vital (FPNV) Positioning Matrix is a critical tool for evaluating vendors within the Autoimmune Disease Drugs Market. This matrix enables business organizations to make well-informed decisions that align with their goals by assessing vendors based on their business strategy and product satisfaction. The four quadrants provide a clear and precise segmentation of vendors, helping users identify the right partners and solutions that best fit their strategic objectives.

Strategy Analysis & Recommendation: Charting a Path to Success in the Autoimmune Disease Drugs Market

A strategic analysis of the Autoimmune Disease Drugs Market is essential for businesses looking to strengthen their global market presence. By reviewing key resources, capabilities, and performance indicators, business organizations can identify growth opportunities and work toward improvement. This approach helps businesses navigate challenges in the competitive landscape and ensures they are well-positioned to capitalize on newer opportunities and drive long-term success.

Key Company Profiles

The report delves into recent significant developments in the Autoimmune Disease Drugs Market, highlighting leading vendors and their innovative profiles. These include Abbott Laboratories, AESKU.GROUP GmbH & Co. KG, AstraZeneca PLC, Beckman Coulter, Inc., Bio-Rad Laboratories, Inc., BioAgilytix Labs, LLC, Biogenuix Medsystems Private Limited, bioMerieux S.A., Exagen, Inc., F. Hoffmann-La Roche AG, Novartis AG, Pfizer, Inc., Sanofi S.A., Siemens Healthineers AG, Thermo Fisher Scientific Inc., Trinity Biotech PLC, and Werfen S.A..

Market Segmentation & Coverage

This research report categorizes the Autoimmune Disease Drugs Market to forecast the revenues and analyze trends in each of the following sub-markets:

  • Based on Indication, market is studied across Diabetes Mellitus Type 1, Multiple Sclerosis, Rare Diseases, and Rheumatic Diseases.
  • Based on Drug Class, market is studied across Anti-Inflammatory, Antihyperglycemic, Immunosuppressants, Interferons, and Nonsteroidal Anti-Inflammatory Drugs.
  • Based on Distribution, market is studied across Hospital Pharmacies, Online Stores, and Retail Pharmacies.
  • Based on Region, market is studied across Americas, Asia-Pacific, and Europe, Middle East & Africa. The Americas is further studied across Argentina, Brazil, Canada, Mexico, and United States. The United States is further studied across California, Florida, Illinois, New York, Ohio, Pennsylvania, and Texas. The Asia-Pacific is further studied across Australia, China, India, Indonesia, Japan, Malaysia, Philippines, Singapore, South Korea, Taiwan, Thailand, and Vietnam. The Europe, Middle East & Africa is further studied across Denmark, Egypt, Finland, France, Germany, Israel, Italy, Netherlands, Nigeria, Norway, Poland, Qatar, Russia, Saudi Arabia, South Africa, Spain, Sweden, Switzerland, Turkey, United Arab Emirates, and United Kingdom.

The report offers a comprehensive analysis of the market, covering key focus areas:

1. Market Penetration: A detailed review of the current market environment, including extensive data from top industry players, evaluating their market reach and overall influence.

2. Market Development: Identifies growth opportunities in emerging markets and assesses expansion potential in established sectors, providing a strategic roadmap for future growth.

3. Market Diversification: Analyzes recent product launches, untapped geographic regions, major industry advancements, and strategic investments reshaping the market.

4. Competitive Assessment & Intelligence: Provides a thorough analysis of the competitive landscape, examining market share, business strategies, product portfolios, certifications, regulatory approvals, patent trends, and technological advancements of key players.

5. Product Development & Innovation: Highlights cutting-edge technologies, R&D activities, and product innovations expected to drive future market growth.

The report also answers critical questions to aid stakeholders in making informed decisions:

1. What is the current market size, and what is the forecasted growth?

2. Which products, segments, and regions offer the best investment opportunities?

3. What are the key technology trends and regulatory influences shaping the market?

4. How do leading vendors rank in terms of market share and competitive positioning?

5. What revenue sources and strategic opportunities drive vendors' market entry or exit strategies?

Table of Contents

1. Preface

  • 1.1. Objectives of the Study
  • 1.2. Market Segmentation & Coverage
  • 1.3. Years Considered for the Study
  • 1.4. Currency & Pricing
  • 1.5. Language
  • 1.6. Stakeholders

2. Research Methodology

  • 2.1. Define: Research Objective
  • 2.2. Determine: Research Design
  • 2.3. Prepare: Research Instrument
  • 2.4. Collect: Data Source
  • 2.5. Analyze: Data Interpretation
  • 2.6. Formulate: Data Verification
  • 2.7. Publish: Research Report
  • 2.8. Repeat: Report Update

3. Executive Summary

4. Market Overview

5. Market Insights

  • 5.1. Market Dynamics
    • 5.1.1. Drivers
      • 5.1.1.1. Increasing incidence of autoimmune diseases rheumatoid arthritis, graves and hashimoto's thyroid disease
      • 5.1.1.2. Growing awareness of autoimmune diseases
      • 5.1.1.3. Improved government assistance, funding, and reimbursement policies
    • 5.1.2. Restraints
      • 5.1.2.1. Associated side effects of autoimmune disease drugs
    • 5.1.3. Opportunities
      • 5.1.3.1. Advancements and availability of late-stage pipeline drugs
      • 5.1.3.2. Ongoing research and innovations in autoimmune disease drugs
    • 5.1.4. Challenges
      • 5.1.4.1. High cost of autoimmune disease medications
  • 5.2. Market Segmentation Analysis
  • 5.3. Porter's Five Forces Analysis
    • 5.3.1. Threat of New Entrants
    • 5.3.2. Threat of Substitutes
    • 5.3.3. Bargaining Power of Customers
    • 5.3.4. Bargaining Power of Suppliers
    • 5.3.5. Industry Rivalry
  • 5.4. PESTLE Analysis
    • 5.4.1. Political
    • 5.4.2. Economic
    • 5.4.3. Social
    • 5.4.4. Technological
    • 5.4.5. Legal
    • 5.4.6. Environmental

6. Autoimmune Disease Drugs Market, by Indication

  • 6.1. Introduction
  • 6.2. Diabetes Mellitus Type 1
  • 6.3. Multiple Sclerosis
  • 6.4. Rare Diseases
  • 6.5. Rheumatic Diseases

7. Autoimmune Disease Drugs Market, by Drug Class

  • 7.1. Introduction
  • 7.2. Anti-Inflammatory
  • 7.3. Antihyperglycemic
  • 7.4. Immunosuppressants
  • 7.5. Interferons
  • 7.6. Nonsteroidal Anti-Inflammatory Drugs

8. Autoimmune Disease Drugs Market, by Distribution

  • 8.1. Introduction
  • 8.2. Hospital Pharmacies
  • 8.3. Online Stores
  • 8.4. Retail Pharmacies

9. Americas Autoimmune Disease Drugs Market

  • 9.1. Introduction
  • 9.2. Argentina
  • 9.3. Brazil
  • 9.4. Canada
  • 9.5. Mexico
  • 9.6. United States

10. Asia-Pacific Autoimmune Disease Drugs Market

  • 10.1. Introduction
  • 10.2. Australia
  • 10.3. China
  • 10.4. India
  • 10.5. Indonesia
  • 10.6. Japan
  • 10.7. Malaysia
  • 10.8. Philippines
  • 10.9. Singapore
  • 10.10. South Korea
  • 10.11. Taiwan
  • 10.12. Thailand
  • 10.13. Vietnam

11. Europe, Middle East & Africa Autoimmune Disease Drugs Market

  • 11.1. Introduction
  • 11.2. Denmark
  • 11.3. Egypt
  • 11.4. Finland
  • 11.5. France
  • 11.6. Germany
  • 11.7. Israel
  • 11.8. Italy
  • 11.9. Netherlands
  • 11.10. Nigeria
  • 11.11. Norway
  • 11.12. Poland
  • 11.13. Qatar
  • 11.14. Russia
  • 11.15. Saudi Arabia
  • 11.16. South Africa
  • 11.17. Spain
  • 11.18. Sweden
  • 11.19. Switzerland
  • 11.20. Turkey
  • 11.21. United Arab Emirates
  • 11.22. United Kingdom

12. Competitive Landscape

  • 12.1. Market Share Analysis, 2023
  • 12.2. FPNV Positioning Matrix, 2023
  • 12.3. Competitive Scenario Analysis
  • 12.4. Strategy Analysis & Recommendation

Companies Mentioned

  • 1. Abbott Laboratories
  • 2. AESKU.GROUP GmbH & Co. KG
  • 3. AstraZeneca PLC
  • 4. Beckman Coulter, Inc.
  • 5. Bio-Rad Laboratories, Inc.
  • 6. BioAgilytix Labs, LLC
  • 7. Biogenuix Medsystems Private Limited
  • 8. bioMerieux S.A.
  • 9. Exagen, Inc.
  • 10. F. Hoffmann-La Roche AG
  • 11. Novartis AG
  • 12. Pfizer, Inc.
  • 13. Sanofi S.A.
  • 14. Siemens Healthineers AG
  • 15. Thermo Fisher Scientific Inc.
  • 16. Trinity Biotech PLC
  • 17. Werfen S.A.

LIST OF FIGURES

  • FIGURE 1. AUTOIMMUNE DISEASE DRUGS MARKET RESEARCH PROCESS
  • FIGURE 2. AUTOIMMUNE DISEASE DRUGS MARKET SIZE, 2023 VS 2030
  • FIGURE 3. GLOBAL AUTOIMMUNE DISEASE DRUGS MARKET SIZE, 2018-2030 (USD MILLION)
  • FIGURE 4. GLOBAL AUTOIMMUNE DISEASE DRUGS MARKET SIZE, BY REGION, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 5. GLOBAL AUTOIMMUNE DISEASE DRUGS MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 6. GLOBAL AUTOIMMUNE DISEASE DRUGS MARKET SIZE, BY INDICATION, 2023 VS 2030 (%)
  • FIGURE 7. GLOBAL AUTOIMMUNE DISEASE DRUGS MARKET SIZE, BY INDICATION, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 8. GLOBAL AUTOIMMUNE DISEASE DRUGS MARKET SIZE, BY DRUG CLASS, 2023 VS 2030 (%)
  • FIGURE 9. GLOBAL AUTOIMMUNE DISEASE DRUGS MARKET SIZE, BY DRUG CLASS, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 10. GLOBAL AUTOIMMUNE DISEASE DRUGS MARKET SIZE, BY DISTRIBUTION, 2023 VS 2030 (%)
  • FIGURE 11. GLOBAL AUTOIMMUNE DISEASE DRUGS MARKET SIZE, BY DISTRIBUTION, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 12. AMERICAS AUTOIMMUNE DISEASE DRUGS MARKET SIZE, BY COUNTRY, 2023 VS 2030 (%)
  • FIGURE 13. AMERICAS AUTOIMMUNE DISEASE DRUGS MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 14. UNITED STATES AUTOIMMUNE DISEASE DRUGS MARKET SIZE, BY STATE, 2023 VS 2030 (%)
  • FIGURE 15. UNITED STATES AUTOIMMUNE DISEASE DRUGS MARKET SIZE, BY STATE, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 16. ASIA-PACIFIC AUTOIMMUNE DISEASE DRUGS MARKET SIZE, BY COUNTRY, 2023 VS 2030 (%)
  • FIGURE 17. ASIA-PACIFIC AUTOIMMUNE DISEASE DRUGS MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 18. EUROPE, MIDDLE EAST & AFRICA AUTOIMMUNE DISEASE DRUGS MARKET SIZE, BY COUNTRY, 2023 VS 2030 (%)
  • FIGURE 19. EUROPE, MIDDLE EAST & AFRICA AUTOIMMUNE DISEASE DRUGS MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 20. AUTOIMMUNE DISEASE DRUGS MARKET SHARE, BY KEY PLAYER, 2023
  • FIGURE 21. AUTOIMMUNE DISEASE DRUGS MARKET, FPNV POSITIONING MATRIX, 2023

LIST OF TABLES

  • TABLE 1. AUTOIMMUNE DISEASE DRUGS MARKET SEGMENTATION & COVERAGE
  • TABLE 2. UNITED STATES DOLLAR EXCHANGE RATE, 2018-2023
  • TABLE 3. GLOBAL AUTOIMMUNE DISEASE DRUGS MARKET SIZE, 2018-2030 (USD MILLION)
  • TABLE 4. GLOBAL AUTOIMMUNE DISEASE DRUGS MARKET SIZE, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 5. GLOBAL AUTOIMMUNE DISEASE DRUGS MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
  • TABLE 6. AUTOIMMUNE DISEASE DRUGS MARKET DYNAMICS
  • TABLE 7. GLOBAL AUTOIMMUNE DISEASE DRUGS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 8. GLOBAL AUTOIMMUNE DISEASE DRUGS MARKET SIZE, BY DIABETES MELLITUS TYPE 1, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 9. GLOBAL AUTOIMMUNE DISEASE DRUGS MARKET SIZE, BY MULTIPLE SCLEROSIS, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 10. GLOBAL AUTOIMMUNE DISEASE DRUGS MARKET SIZE, BY RARE DISEASES, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 11. GLOBAL AUTOIMMUNE DISEASE DRUGS MARKET SIZE, BY RHEUMATIC DISEASES, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 12. GLOBAL AUTOIMMUNE DISEASE DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
  • TABLE 13. GLOBAL AUTOIMMUNE DISEASE DRUGS MARKET SIZE, BY ANTI-INFLAMMATORY, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 14. GLOBAL AUTOIMMUNE DISEASE DRUGS MARKET SIZE, BY ANTIHYPERGLYCEMIC, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 15. GLOBAL AUTOIMMUNE DISEASE DRUGS MARKET SIZE, BY IMMUNOSUPPRESSANTS, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 16. GLOBAL AUTOIMMUNE DISEASE DRUGS MARKET SIZE, BY INTERFERONS, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 17. GLOBAL AUTOIMMUNE DISEASE DRUGS MARKET SIZE, BY NONSTEROIDAL ANTI-INFLAMMATORY DRUGS, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 18. GLOBAL AUTOIMMUNE DISEASE DRUGS MARKET SIZE, BY DISTRIBUTION, 2018-2030 (USD MILLION)
  • TABLE 19. GLOBAL AUTOIMMUNE DISEASE DRUGS MARKET SIZE, BY HOSPITAL PHARMACIES, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 20. GLOBAL AUTOIMMUNE DISEASE DRUGS MARKET SIZE, BY ONLINE STORES, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 21. GLOBAL AUTOIMMUNE DISEASE DRUGS MARKET SIZE, BY RETAIL PHARMACIES, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 22. AMERICAS AUTOIMMUNE DISEASE DRUGS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 23. AMERICAS AUTOIMMUNE DISEASE DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
  • TABLE 24. AMERICAS AUTOIMMUNE DISEASE DRUGS MARKET SIZE, BY DISTRIBUTION, 2018-2030 (USD MILLION)
  • TABLE 25. AMERICAS AUTOIMMUNE DISEASE DRUGS MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
  • TABLE 26. ARGENTINA AUTOIMMUNE DISEASE DRUGS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 27. ARGENTINA AUTOIMMUNE DISEASE DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
  • TABLE 28. ARGENTINA AUTOIMMUNE DISEASE DRUGS MARKET SIZE, BY DISTRIBUTION, 2018-2030 (USD MILLION)
  • TABLE 29. BRAZIL AUTOIMMUNE DISEASE DRUGS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 30. BRAZIL AUTOIMMUNE DISEASE DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
  • TABLE 31. BRAZIL AUTOIMMUNE DISEASE DRUGS MARKET SIZE, BY DISTRIBUTION, 2018-2030 (USD MILLION)
  • TABLE 32. CANADA AUTOIMMUNE DISEASE DRUGS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 33. CANADA AUTOIMMUNE DISEASE DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
  • TABLE 34. CANADA AUTOIMMUNE DISEASE DRUGS MARKET SIZE, BY DISTRIBUTION, 2018-2030 (USD MILLION)
  • TABLE 35. MEXICO AUTOIMMUNE DISEASE DRUGS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 36. MEXICO AUTOIMMUNE DISEASE DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
  • TABLE 37. MEXICO AUTOIMMUNE DISEASE DRUGS MARKET SIZE, BY DISTRIBUTION, 2018-2030 (USD MILLION)
  • TABLE 38. UNITED STATES AUTOIMMUNE DISEASE DRUGS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 39. UNITED STATES AUTOIMMUNE DISEASE DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
  • TABLE 40. UNITED STATES AUTOIMMUNE DISEASE DRUGS MARKET SIZE, BY DISTRIBUTION, 2018-2030 (USD MILLION)
  • TABLE 41. UNITED STATES AUTOIMMUNE DISEASE DRUGS MARKET SIZE, BY STATE, 2018-2030 (USD MILLION)
  • TABLE 42. ASIA-PACIFIC AUTOIMMUNE DISEASE DRUGS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 43. ASIA-PACIFIC AUTOIMMUNE DISEASE DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
  • TABLE 44. ASIA-PACIFIC AUTOIMMUNE DISEASE DRUGS MARKET SIZE, BY DISTRIBUTION, 2018-2030 (USD MILLION)
  • TABLE 45. ASIA-PACIFIC AUTOIMMUNE DISEASE DRUGS MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
  • TABLE 46. AUSTRALIA AUTOIMMUNE DISEASE DRUGS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 47. AUSTRALIA AUTOIMMUNE DISEASE DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
  • TABLE 48. AUSTRALIA AUTOIMMUNE DISEASE DRUGS MARKET SIZE, BY DISTRIBUTION, 2018-2030 (USD MILLION)
  • TABLE 49. CHINA AUTOIMMUNE DISEASE DRUGS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 50. CHINA AUTOIMMUNE DISEASE DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
  • TABLE 51. CHINA AUTOIMMUNE DISEASE DRUGS MARKET SIZE, BY DISTRIBUTION, 2018-2030 (USD MILLION)
  • TABLE 52. INDIA AUTOIMMUNE DISEASE DRUGS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 53. INDIA AUTOIMMUNE DISEASE DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
  • TABLE 54. INDIA AUTOIMMUNE DISEASE DRUGS MARKET SIZE, BY DISTRIBUTION, 2018-2030 (USD MILLION)
  • TABLE 55. INDONESIA AUTOIMMUNE DISEASE DRUGS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 56. INDONESIA AUTOIMMUNE DISEASE DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
  • TABLE 57. INDONESIA AUTOIMMUNE DISEASE DRUGS MARKET SIZE, BY DISTRIBUTION, 2018-2030 (USD MILLION)
  • TABLE 58. JAPAN AUTOIMMUNE DISEASE DRUGS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 59. JAPAN AUTOIMMUNE DISEASE DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
  • TABLE 60. JAPAN AUTOIMMUNE DISEASE DRUGS MARKET SIZE, BY DISTRIBUTION, 2018-2030 (USD MILLION)
  • TABLE 61. MALAYSIA AUTOIMMUNE DISEASE DRUGS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 62. MALAYSIA AUTOIMMUNE DISEASE DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
  • TABLE 63. MALAYSIA AUTOIMMUNE DISEASE DRUGS MARKET SIZE, BY DISTRIBUTION, 2018-2030 (USD MILLION)
  • TABLE 64. PHILIPPINES AUTOIMMUNE DISEASE DRUGS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 65. PHILIPPINES AUTOIMMUNE DISEASE DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
  • TABLE 66. PHILIPPINES AUTOIMMUNE DISEASE DRUGS MARKET SIZE, BY DISTRIBUTION, 2018-2030 (USD MILLION)
  • TABLE 67. SINGAPORE AUTOIMMUNE DISEASE DRUGS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 68. SINGAPORE AUTOIMMUNE DISEASE DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
  • TABLE 69. SINGAPORE AUTOIMMUNE DISEASE DRUGS MARKET SIZE, BY DISTRIBUTION, 2018-2030 (USD MILLION)
  • TABLE 70. SOUTH KOREA AUTOIMMUNE DISEASE DRUGS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 71. SOUTH KOREA AUTOIMMUNE DISEASE DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
  • TABLE 72. SOUTH KOREA AUTOIMMUNE DISEASE DRUGS MARKET SIZE, BY DISTRIBUTION, 2018-2030 (USD MILLION)
  • TABLE 73. TAIWAN AUTOIMMUNE DISEASE DRUGS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 74. TAIWAN AUTOIMMUNE DISEASE DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
  • TABLE 75. TAIWAN AUTOIMMUNE DISEASE DRUGS MARKET SIZE, BY DISTRIBUTION, 2018-2030 (USD MILLION)
  • TABLE 76. THAILAND AUTOIMMUNE DISEASE DRUGS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 77. THAILAND AUTOIMMUNE DISEASE DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
  • TABLE 78. THAILAND AUTOIMMUNE DISEASE DRUGS MARKET SIZE, BY DISTRIBUTION, 2018-2030 (USD MILLION)
  • TABLE 79. VIETNAM AUTOIMMUNE DISEASE DRUGS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 80. VIETNAM AUTOIMMUNE DISEASE DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
  • TABLE 81. VIETNAM AUTOIMMUNE DISEASE DRUGS MARKET SIZE, BY DISTRIBUTION, 2018-2030 (USD MILLION)
  • TABLE 82. EUROPE, MIDDLE EAST & AFRICA AUTOIMMUNE DISEASE DRUGS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 83. EUROPE, MIDDLE EAST & AFRICA AUTOIMMUNE DISEASE DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
  • TABLE 84. EUROPE, MIDDLE EAST & AFRICA AUTOIMMUNE DISEASE DRUGS MARKET SIZE, BY DISTRIBUTION, 2018-2030 (USD MILLION)
  • TABLE 85. EUROPE, MIDDLE EAST & AFRICA AUTOIMMUNE DISEASE DRUGS MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
  • TABLE 86. DENMARK AUTOIMMUNE DISEASE DRUGS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 87. DENMARK AUTOIMMUNE DISEASE DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
  • TABLE 88. DENMARK AUTOIMMUNE DISEASE DRUGS MARKET SIZE, BY DISTRIBUTION, 2018-2030 (USD MILLION)
  • TABLE 89. EGYPT AUTOIMMUNE DISEASE DRUGS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 90. EGYPT AUTOIMMUNE DISEASE DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
  • TABLE 91. EGYPT AUTOIMMUNE DISEASE DRUGS MARKET SIZE, BY DISTRIBUTION, 2018-2030 (USD MILLION)
  • TABLE 92. FINLAND AUTOIMMUNE DISEASE DRUGS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 93. FINLAND AUTOIMMUNE DISEASE DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
  • TABLE 94. FINLAND AUTOIMMUNE DISEASE DRUGS MARKET SIZE, BY DISTRIBUTION, 2018-2030 (USD MILLION)
  • TABLE 95. FRANCE AUTOIMMUNE DISEASE DRUGS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 96. FRANCE AUTOIMMUNE DISEASE DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
  • TABLE 97. FRANCE AUTOIMMUNE DISEASE DRUGS MARKET SIZE, BY DISTRIBUTION, 2018-2030 (USD MILLION)
  • TABLE 98. GERMANY AUTOIMMUNE DISEASE DRUGS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 99. GERMANY AUTOIMMUNE DISEASE DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
  • TABLE 100. GERMANY AUTOIMMUNE DISEASE DRUGS MARKET SIZE, BY DISTRIBUTION, 2018-2030 (USD MILLION)
  • TABLE 101. ISRAEL AUTOIMMUNE DISEASE DRUGS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 102. ISRAEL AUTOIMMUNE DISEASE DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
  • TABLE 103. ISRAEL AUTOIMMUNE DISEASE DRUGS MARKET SIZE, BY DISTRIBUTION, 2018-2030 (USD MILLION)
  • TABLE 104. ITALY AUTOIMMUNE DISEASE DRUGS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 105. ITALY AUTOIMMUNE DISEASE DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
  • TABLE 106. ITALY AUTOIMMUNE DISEASE DRUGS MARKET SIZE, BY DISTRIBUTION, 2018-2030 (USD MILLION)
  • TABLE 107. NETHERLANDS AUTOIMMUNE DISEASE DRUGS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 108. NETHERLANDS AUTOIMMUNE DISEASE DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
  • TABLE 109. NETHERLANDS AUTOIMMUNE DISEASE DRUGS MARKET SIZE, BY DISTRIBUTION, 2018-2030 (USD MILLION)
  • TABLE 110. NIGERIA AUTOIMMUNE DISEASE DRUGS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 111. NIGERIA AUTOIMMUNE DISEASE DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
  • TABLE 112. NIGERIA AUTOIMMUNE DISEASE DRUGS MARKET SIZE, BY DISTRIBUTION, 2018-2030 (USD MILLION)
  • TABLE 113. NORWAY AUTOIMMUNE DISEASE DRUGS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 114. NORWAY AUTOIMMUNE DISEASE DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
  • TABLE 115. NORWAY AUTOIMMUNE DISEASE DRUGS MARKET SIZE, BY DISTRIBUTION, 2018-2030 (USD MILLION)
  • TABLE 116. POLAND AUTOIMMUNE DISEASE DRUGS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 117. POLAND AUTOIMMUNE DISEASE DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
  • TABLE 118. POLAND AUTOIMMUNE DISEASE DRUGS MARKET SIZE, BY DISTRIBUTION, 2018-2030 (USD MILLION)
  • TABLE 119. QATAR AUTOIMMUNE DISEASE DRUGS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 120. QATAR AUTOIMMUNE DISEASE DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
  • TABLE 121. QATAR AUTOIMMUNE DISEASE DRUGS MARKET SIZE, BY DISTRIBUTION, 2018-2030 (USD MILLION)
  • TABLE 122. RUSSIA AUTOIMMUNE DISEASE DRUGS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 123. RUSSIA AUTOIMMUNE DISEASE DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
  • TABLE 124. RUSSIA AUTOIMMUNE DISEASE DRUGS MARKET SIZE, BY DISTRIBUTION, 2018-2030 (USD MILLION)
  • TABLE 125. SAUDI ARABIA AUTOIMMUNE DISEASE DRUGS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 126. SAUDI ARABIA AUTOIMMUNE DISEASE DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
  • TABLE 127. SAUDI ARABIA AUTOIMMUNE DISEASE DRUGS MARKET SIZE, BY DISTRIBUTION, 2018-2030 (USD MILLION)
  • TABLE 128. SOUTH AFRICA AUTOIMMUNE DISEASE DRUGS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 129. SOUTH AFRICA AUTOIMMUNE DISEASE DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
  • TABLE 130. SOUTH AFRICA AUTOIMMUNE DISEASE DRUGS MARKET SIZE, BY DISTRIBUTION, 2018-2030 (USD MILLION)
  • TABLE 131. SPAIN AUTOIMMUNE DISEASE DRUGS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 132. SPAIN AUTOIMMUNE DISEASE DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
  • TABLE 133. SPAIN AUTOIMMUNE DISEASE DRUGS MARKET SIZE, BY DISTRIBUTION, 2018-2030 (USD MILLION)
  • TABLE 134. SWEDEN AUTOIMMUNE DISEASE DRUGS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 135. SWEDEN AUTOIMMUNE DISEASE DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
  • TABLE 136. SWEDEN AUTOIMMUNE DISEASE DRUGS MARKET SIZE, BY DISTRIBUTION, 2018-2030 (USD MILLION)
  • TABLE 137. SWITZERLAND AUTOIMMUNE DISEASE DRUGS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 138. SWITZERLAND AUTOIMMUNE DISEASE DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
  • TABLE 139. SWITZERLAND AUTOIMMUNE DISEASE DRUGS MARKET SIZE, BY DISTRIBUTION, 2018-2030 (USD MILLION)
  • TABLE 140. TURKEY AUTOIMMUNE DISEASE DRUGS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 141. TURKEY AUTOIMMUNE DISEASE DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
  • TABLE 142. TURKEY AUTOIMMUNE DISEASE DRUGS MARKET SIZE, BY DISTRIBUTION, 2018-2030 (USD MILLION)
  • TABLE 143. UNITED ARAB EMIRATES AUTOIMMUNE DISEASE DRUGS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 144. UNITED ARAB EMIRATES AUTOIMMUNE DISEASE DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
  • TABLE 145. UNITED ARAB EMIRATES AUTOIMMUNE DISEASE DRUGS MARKET SIZE, BY DISTRIBUTION, 2018-2030 (USD MILLION)
  • TABLE 146. UNITED KINGDOM AUTOIMMUNE DISEASE DRUGS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 147. UNITED KINGDOM AUTOIMMUNE DISEASE DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
  • TABLE 148. UNITED KINGDOM AUTOIMMUNE DISEASE DRUGS MARKET SIZE, BY DISTRIBUTION, 2018-2030 (USD MILLION)
  • TABLE 149. AUTOIMMUNE DISEASE DRUGS MARKET SHARE, BY KEY PLAYER, 2023
  • TABLE 150. AUTOIMMUNE DISEASE DRUGS MARKET, FPNV POSITIONING MATRIX, 2023